Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Kilitch Drugs (India) Ltd

Pharmaceuticals & Biotechnology | Small Cap

Kilitch Drugs (India) Ltd Health Insights
Health Score : 6.61Health Score : 6.61

Kilitch Drugs demonstrates a mixed financial performance. The company shows strong growth and profitability, driven by substantial increases in revenue, operating profit, and earnings per share. Its solvency is excellent, indicating a low debt burden and strong equity. However, efficiency and liquidity pose some concerns. While inventory management is efficient, asset turnover and receivable collection are less so. Liquidity ratios suggest potential challenges in meeting short-term obligations. The company's coverage ratios are mixed, with strong interest coverage offset by the absence of dividend coverage. Overall, Kilitch Drugs exhibits promising growth and profitability, but needs to address efficiency and liquidity to ensure long-term financial stability. The healthcare industry is subject to regulatory changes and market competition, both of which could impact future performance.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Kilitch Drugs (India) Ltd Health Insights
Health Score : 6.61Health Score : 6.61

Kilitch Drugs demonstrates a mixed financial performance. The company shows strong growth and profitability, driven by substantial increases in revenue, operating profit, and earnings per share. Its solvency is excellent, indicating a low debt burden and strong equity. However, efficiency and liquidity pose some concerns. While inventory management is efficient, asset turnover and receivable collection are less so. Liquidity ratios suggest potential challenges in meeting short-term obligations. The company's coverage ratios are mixed, with strong interest coverage offset by the absence of dividend coverage. Overall, Kilitch Drugs exhibits promising growth and profitability, but needs to address efficiency and liquidity to ensure long-term financial stability. The healthcare industry is subject to regulatory changes and market competition, both of which could impact future performance.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

20.05

Neutral

Industry Median

28.62

Neutral
Neutral

Small Cap Median

27.17

Neutral

P/E RATIO

21.54

P/B RATIO

2.32

Undervalued

Industry Median

3.17

Undervalued
Neutral

Small Cap Median

2.62

Neutral

P/S RATIO

2.74

Neutral

Industry Median

3.42

Neutral
Neutral

Small Cap Median

2.55

Neutral

Others

Neutral

PEG RATIO

0.00

Neutral
Overvalued

EV/EBITDA RATIO

13.98

Overvalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹185.86 as on Jun 19, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 10.00

The company demonstrates excellent growth across all key metrics, including revenue, operating profit, earnings per share, assets, and net income. This indicates a strong growth trajectory and effective management strategies. The weighted average calculation confirms this positive trend, reflecting a consistent and robust growth performance.

ExcellentRevenue Growth RateExcellent
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
ExcellentAsset Growth RateExcellent
ExcellentNet Income Growth RateExcellent
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate67.6522.811028.5718.69
Operating Profit Growth Rate1008033.3333.3315.62
Earnings Per Share (EPS) Growth99.0841.9435.3982.9713.11
Asset Growth Rate3.454.769.0930.4246.33
Net Income Growth Rate5033.337578.5720
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 2.40

The financial ratios of the company indicate areas of concern. Adjusted Earnings Per Share, Book Value Per Share and Capital Expenditure is not up to the mark. Dividend Per Share (DPS) is zero. There is a need to focus on improving key financial metrics to enhance overall financial health and investor confidence. The weighted average calculation highlights the areas needing improvement and strategic adjustments.

PoorAdjusted Earnings Per Share (Adjusted EPS)Poor
WeakCash Earnings Per Share (Cash EPS)Weak
PoorBook Value Per SharePoor
PoorDividend Per Share (DPS)Poor
PoorCapital Expenditures (CapEx)Poor
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)2.53.247.5312.768.38
Cash Earnings Per Share (Cash EPS)57.510.6217.59.71
Book Value Per Share87.595110126.2580
Dividend Per Share (DPS)00000
Capital Expenditures (CapEx)84647100
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 9.80

The company demonstrates excellent profitability, with strong gross profit margin, return on capital employed, return on equity, return on assets, operating margin, and net margin. This indicates effective cost management, efficient asset utilization, and strong earnings generation. The weighted average calculation confirms this positive trend, reflecting a consistently robust profitability performance.

ExcellentGross Profit MarginExcellent
ExcellentReturn on Capital Employed (ROCE)Excellent
ExcellentReturn on Equity (ROE)Excellent
GoodReturn on Assets (ROA)Good
ExcellentOperating MarginExcellent
ExcellentNet MarginExcellent
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin7.021013.6414.6514.04
Return on Capital Employed (ROCE)610131614
Return on Equity (ROE)4.295.267.9512.3810.71
Return on Assets (ROA)4.768.181010.228.08
Operating Margin8.7712.8615.5816.1615.74
Net Margin5.265.719.0912.6312.77
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 4.67

The company's efficiency ratios present a mixed picture. While inventory turnover and days sales in inventory are excellent, indicating efficient inventory management, fixed asset turnover, receivables turnover, receivable days, and capital turnover are below average. This suggests potential issues with asset utilization and collection efficiency. The weighted average calculation highlights the need for improvements in these areas to optimize overall efficiency.

PoorFixed Asset Turnover RatioPoor
ExcellentInventory Turnover RatioExcellent
PoorReceivables Turnover RatioPoor
ExcellentDays Sales in Inventory RatioExcellent
PoorReceivable DaysPoor
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio1.752.192.483.093.51
Inventory Turnover Ratio23.563644.3317.8915.04
Receivables Turnover Ratio3.562.952.632.682.29
Days Sales in Inventory Ratio15.4910.148.2320.424.27
Receivable Days102.53123.73138.78136.19159.39
Capital Turnover Ratio0.810.920.880.860.69
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 6.80

The company's coverage ratios present a mixed performance. While the interest coverage ratio is excellent, indicating a strong ability to meet interest obligations, the equity dividend coverage ratio is poor, reflecting the absence of dividend payouts. This suggests that the company is prioritizing debt obligations over shareholder returns. The weighted average calculation highlights the need for a more balanced approach to coverage management.

ExcellentInterest Coverage RatioExcellent
PoorEquity Dividend Coverage RatioPoor
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio113.44.177.87.5
Equity Dividend Coverage Ratio
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company exhibits excellent solvency, with low debt ratios and a high equity ratio. This indicates a strong financial structure and a minimal reliance on debt financing. This provides a stable base for future growth and reduces the risk of financial distress. The weighted average calculation confirms this positive trend, reflecting a consistently strong solvency position.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0000.120.17
Debt to Equity Ratio0000.140.2
Equity Ratio1110.880.83
Debt To Asset Ratio0000.090.13
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 5.36

The company's liquidity position reveals a mixed performance. While the Quick Ratio indicates an above-average ability to meet short-term obligations with its most liquid assets, the Current, Cash, and Operating Cash Flow Ratios suggest potential challenges in meeting short-term liabilities. The healthcare industry often requires maintaining sufficient liquidity to manage operational expenses and unforeseen costs. The weighted average calculation highlights recent trends, indicating areas needing attention to ensure financial stability.

WeakCurrent RatioWeak
GoodQuick RatioGood
WeakCash RatioWeak
WeakOperating Cash Flow RatioWeak
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio1.011.321.561.551.48
Quick Ratio0.941.291.51.371.38
Cash Ratio0.140.290.310.120.14
Operating Cash Flow Ratio0.090.04-0.030.220.2
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 19 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Accent Microcell Ltd7.9624.25Neutral57.0018.2844.00
2NGL Fine Chem Ltd6.9839.22Overvalued73.0067.3948.00
3Medico Remedies Ltd6.6137.70Overvalued17.001.5813.00
4Kilitch Drugs (India) Ltd6.6121.54Neutral37.009.2730.00
5Kopran Ltd6.6025.82Neutral62.006.3026.00
6SMS Lifesciences India Ltd6.5921.20Undervalued45.0070.6819.00
7Infinium Pharmachem Ltd6.4226.90Neutral22.006.4314.00
8Sakar Healthcare Ltd5.8158.66Highly Overvalued69.0013.7030.00
9Medicamen Biotech Ltd5.7332.19Neutral20.006.9410.00
10Aarey Drugs & Pharmaceuticals Ltd5.7359.71Neutral7.001.404.00
11Albert David Ltd5.63-272.47Neutral5.00-2.62-1.00
12BPL Ltd5.46-31.11Neutral-4.82-3.00-8.55
13Zim Laboratories Ltd5.4141.96Neutral30.001.116.00
14Remus Pharmaceuticals Ltd5.3125.48Neutral57.0020.9746.00
15Ind-Swift Laboratories Ltd4.9539.28Neutral45.004.8941.00
16Venus Remedies Ltd4.8323.37Neutral147.0074.30103.00
17Lyka Labs Ltd4.77-23.98Neutral-4.00-9.05-10.00
18Wanbury Ltd4.6528.62Neutral88.0018.9343.00
19Nectar Lifescience Ltd3.83-2.67Neutral-59.00-2.95-293.00
Management Assessment Summary
OrangeBalanced Management

The management effectiveness of Kilitch Drugs (India) Ltd is a mix of strengths and weaknesses. The company has shown good compounded profit growth in the past, along with improved returns on capital. However, rising debt and inconsistent quarterly sales and profit growth are concerns. The promoters' stable holding indicates confidence. Overall, management's ability to maintain growth while managing debt will be critical.

Category Metric Value Assessment
PROS Compounded Profit Growth (5Y, 3Y) 161%, 67% Strong profit expansion.
Return on Capital Employed (ROCE) 17% Improving capital efficiency.
Promoter Holding 69.23% Stable promoter confidence.
CONS Debt/Equity Ratio Increasing Borrowings Leverage is under control.
Quarterly Sales Growth Volatility Fluctuations Inconsistent sales performance.
Absence of Institutional Holding (FII/DII) 0% Lack of institutional interest.
AverageFinancial Performance & GrowthAverage
GoodCapital Efficiency & ReturnsGood
AverageFinancial Health & PrudenceAverage
GoodShareholding & Ownership StructureGood
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

The risk assessment for Kilitch Drugs indicates a moderate level of risk due to increasing debt levels and fluctuating sales and profit growth. The risk profile is balanced by stable promoter holding.

AverageSegment performance volatilityAverage
01.

Segment performance volatility

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10183.50Bullish
  3. SMA 20182.74Bullish
  4. SMA 50184.34Bullish
  5. EMA 10183.95Bullish
  6. EMA 20183.65Bullish
  7. EMA 50183.22Bullish
  8. DEMA 10184.74Bullish
  9. DEMA 20183.74Bullish
  10. DEMA 50184.47Bullish
  11. TEMA 10185.58Bullish
  12. TEMA 20183.97Bullish
  13. TEMA 50183.89Bullish
  14. MACD0.19Bullish
  15. ADX27.60Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI62.84Neutral
  3. CCI238.23Overbought
  4. ROC 92.68Bullish
  5. ROC 143.58Bullish
  6. ROC 251.37Bullish
  7. Stoch K56.98Neutral
  8. Stoch D41.29Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper186.39Overbought
  3. BB Middle182.74Neutral
  4. BB Lower179.08Neutral
  5. ATR2.98High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI69.27Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10183.39Bullish
  3. SMA 20184.02Bullish
  4. SMA 50181.04Bullish
  5. EMA 10184.11Bullish
  6. EMA 20183.69Bullish
  7. EMA 50181.90Bullish
  8. DEMA 10184.71Bullish
  9. DEMA 20184.50Bullish
  10. DEMA 50185.61Bullish
  11. TEMA 10185.42Bullish
  12. TEMA 20184.18Bullish
  13. TEMA 50184.32Bullish
  14. MACD0.59Bullish
  15. ADX32.70Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI59.51Neutral
  3. CCI114.84Overbought
  4. ROC 93.59Bullish
  5. ROC 142.21Bullish
  6. ROC 253.34Bullish
  7. Stoch K56.64Neutral
  8. Stoch D47.07Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper188.84Neutral
  3. BB Middle184.02Neutral
  4. BB Lower179.20Neutral
  5. ATR4.39High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI66.70Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10184.00Bullish
  3. SMA 20182.38Bullish
  4. SMA 50179.65Bullish
  5. EMA 10183.90Bullish
  6. EMA 20182.62Bullish
  7. EMA 50177.34Bullish
  8. DEMA 10184.95Bullish
  9. DEMA 20185.28Bullish
  10. DEMA 50187.12Bullish
  11. TEMA 10184.87Bullish
  12. TEMA 20184.69Bullish
  13. TEMA 50N/AN/A
  14. MACD1.94Bearish
  15. ADX27.95Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI57.42Neutral
  3. CCI63.21Neutral
  4. ROC 90.01Bullish
  5. ROC 142.95Bullish
  6. ROC 256.99Bullish
  7. Stoch K39.82Neutral
  8. Stoch D37.56Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper193.89Neutral
  3. BB Middle182.38Neutral
  4. BB Lower170.86Neutral
  5. ATR6.97High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI60.77Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (22)
  1. IndicatorValueSignal
  2. SMA 10181.59Bullish
  3. SMA 20181.08Bullish
  4. SMA 50161.98Bullish
  5. SMA 100160.84Bullish
  6. SMA 200169.28Bullish
  7. EMA 10182.11Bullish
  8. EMA 20178.52Bullish
  9. EMA 50169.36Bullish
  10. EMA 100166.46Bullish
  11. EMA 200169.68Bullish
  12. DEMA 10184.58Bearish
  13. DEMA 20186.23Bearish
  14. DEMA 50178.03Bullish
  15. DEMA 100165.31Bullish
  16. DEMA 200164.00Bullish
  17. TEMA 10183.66Bearish
  18. TEMA 20185.91Bearish
  19. TEMA 50186.95Bearish
  20. TEMA 100172.18Bullish
  21. TEMA 200158.61Bullish
  22. MACD5.40Bearish
  23. ADX32.58Strong Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI56.09Neutral
  3. CCI26.64Neutral
  4. ROC 140.16Bullish
  5. ROC 2516.38Bullish
  6. Stoch K57.31Neutral
  7. Stoch D60.86Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper191.06Neutral
  3. BB Middle181.08Neutral
  4. BB Lower171.10Neutral
  5. ATR10.54Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI54.93Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Trend Indicators (10)
  1. IndicatorValueSignal
  2. SMA 20159.24Bullish
  3. SMA 50176.17Bullish
  4. EMA 20164.96Bullish
  5. EMA 50169.45Bullish
  6. DEMA 20164.38Bullish
  7. DEMA 50164.87Bullish
  8. TEMA 20171.52Bullish
  9. TEMA 50156.79Bullish
  10. MACD1.21Bullish
  11. ADX19.15Weak Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI56.09Neutral
  3. CCI23.62Neutral
  4. ROC 1418.11Bullish
  5. ROC 2511.59Bullish
  6. Stoch K80.82Overbought
  7. Stoch D78.55Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper191.24Neutral
  3. BB Middle159.24Neutral
  4. BB Lower127.25Neutral
  5. ATR19.92High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI81.70Overbought

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 6159.11Bullish
  3. SMA 12174.61Bullish
  4. SMA 24172.45Bullish
  5. EMA 6163.84Bullish
  6. EMA 12167.66Bullish
  7. EMA 24165.38Bullish
  8. DEMA 6161.01Bullish
  9. DEMA 12163.53Bullish
  10. DEMA 24178.72Bullish
  11. TEMA 6164.66Bullish
  12. TEMA 12156.31Bullish
  13. TEMA 24168.35Bullish
  14. MACD21.00Bearish
  15. ADX38.94Strong Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI55.60Neutral
  3. CCI51.56Neutral
  4. ROC 252.77Bullish
  5. ROC 50122.75Bullish
  6. Stoch K39.76Neutral
  7. Stoch D53.21Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper221.79Neutral
  3. BB Middle173.06Neutral
  4. BB Lower124.34Neutral
  5. ATR37.81High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI83.96Overbought